Essential TremorPhase 2NCT07103265
Developing a New LIFU Neuromodulation Method to Suppress Tremor
A Phase 2 study testing Transcranial focused ultrasound stimulation in people with Essential Tremor, run by University of Calgary.
Trial summary
The investigators aim to apply low intensity focused ultrasound neuromodulation to patients with essential tremor to evaluate the efficacy of this intervention in reducing the amplitude of hand tremor compared to sham stimulation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Essential Tremor
- What is being tested?
- Transcranial focused ultrasound stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- 15 Sep 2025to 15 Jul 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of Essential Tremor OR Diagnosis of Parkinson's Disease
Who cannot join
- Presence of any neurological diagnosis other than Essential Tremor and Parkinson's Disease
- Family history of Essential Tremor OR Parkinson's Disease
- Inability to undergo MRI or attend to the experimental study sessions
About this study
Official title: Developing a New Low-intensity Focused Ultrasound (LIFU) Neuromodulation Method to Suppress Tremor
The investigators aim to apply low intensity focused ultrasound neuromodulation to patients with essential tremor to evaluate the efficacy of this intervention in reducing the amplitude of hand tremor compared to sham stimulation.
Read the detailed description
Transcranial ultrasound stimulation is a non-invasive brain stimulation that uses low intensity focused ultrasound (LIFU) to modulate neural activity with high spatial precision (Zadeh et al., 2024). Several human and animal studies have demonstrated that LIFU can produce lasting neuromodulatory effects, including both excitatory and inhibitory responses in the primary motor cortex (Zadeh et al., 2024). Furthermore, evidence suggests that LIFU is capable of inducing plasticity in the human brain that resembles long term potentiation or long-term depression (Zeng et al., 2024). The ability of LIFU to induce bidirectional effects, either excitatory or inhibitory, depending on sonication parameters, offers a level of flexibility in tailoring neuromodulatory interventions to individual patient needs and specific neural circuit dysfunctions. Combined with real-time neuronavigation and acoustic modeling tools, LIFU provides a promising platform for precise, personalized, and non-invasive brain stimulation. The modulatory effect of LIFU depends on sonication parameters such as frequency, attenuation, and pulse repetition frequency (Zeng et al., 2024; Manuel et al., 2020), and evidence from both preclinical and clinical studies suggests these effects can persist beyond the stimulation period consistent with long-term potentiation or long-term depression-like plasticity mechanisms (Fomenko et al., 2020; Zadeh et al., 2024).
Unlike other neuromodulatory techniques such as transcranial magnetic stimulation and transcranial direct current stimulation, LIFU offers the unique capability to reach deep brain structures while maintaining a focal spatial resolution. This advantage of precise targeting of deep brain regions such as the thalamus without the need for surgical intervention make LIFU a highly useful modality for investigating disorders (Legon et al., 2018). Structures like the ventral intermediate nucleus (Vim) of the thalamus, commonly implicated in movement disorders such as essential tremor and Parkinson's disease, can be non-invasively stimulated using LIFU to modulate aberrant neural activity.
In a previous study, we piloted an ultrasound transducer integrated with standard optical tracking-based neuro-navigation to establish a safety and tolerability benchmark for LIFU to reduce tremor in patients with Essential Tremor or Parkinson's disease, while also optimizing stimulation parameters prior to broader clinical application. Our open label study, currently under review for publication, demonstrated high efficacy and safety of our system to transiently reduce, in the short term, tremor amplitude measured using accelerometric recordings. By integrating rigorous screening, controlled stimulation parameters, and standardized monitoring protocols, we propose here a randomized sham-controlled study to advance knowledge on efficacy and safety of this technology in a larger clinical sample of patients with these diagnoses. As LIFU continues to expand into therapeutic realms, such foundational research will be essential for supporting its evidence-based integration into neuroscience and medicine.
Objectives. AIM: To determine if we can low intensity focused ultrasound (LIFU, a neuromodulatory form of ultrasound) in the laboratory setting can transiently suppress tremor when targeting motor thalamus in patients with tremor.
HYPOTHESIS: Specific LIFU patterns applied to deep thalamic targets will transiently induce reduce tremor in patients with tremor.
IMPACT: If successful, we could use LIFU to help predict potential efficacy of permanent lesioning on tremor as well as support further investigation of LIFU as a novel non-invasive neuromodulation strategy for tremor.
- Conditions
- Essential Tremor
- Being tested
- Transcranial focused ultrasound stimulation, Sham stimulation
- Medical subject headings
- Essential Tremor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcranial focused ultrasound stimulationDevice
Parameters Range of values Fundamental frequency 250 kHz Transducer diameter 15 cm Focal distance 13.5 cm (steerable +/- 5-10 mm from the center) Pulse repetition frequency 100 Hz Duty cycle 10% Duration 2 min for each of the 7 foci Peak spatial intensity (Isppa) 10.0 W/cm2 Peak temporal average intensity (Ispta) 1.2 W/cm2 Mechanical index (MI) 0.48 * Thermal index (TI) 0.8oC **
Sham stimulationDevice
Same set-up as for real stimulation but with without delivering any ultrasound stimulation
| Study group | Role | What they receive |
|---|---|---|
| Real stimulation | Experimental | We use an in-house developed focused ultrasound system that uses a 128-element phased array transducer (diameter of 135 mm, F#=0.8) operating at 700 kHz and mounted on a specialized arm for stereotactic neuronavigation. It has been tested in normal subjects targeting cortical structures (REB#19-1614, #21-0959), and in thalamus for the pilot data collection for this project (REB#22-1437).
Patients will be seated comfortably in a chair equipped with neuronavigation (BrainSight, Rogue) positioning the custom LIFU array. The LIFU array will be applied to the scalp, with hair parted and ultrasound gel applied, and held in place using the neuronavigation arm. Receives: Device: Transcranial focused ultrasound stimulation |
| Sham stimulation | Sham comparator | Same setting as Real stimulation, but without delivering any ultrasound stimulation. Receives: Device: Sham stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in power spectral density (PSD) of tremor accelerometric trace between post-sonication (Round 1) and baseline
This outcome will be measured using triaxial accelerometry performed on the participants' index finger (treated side). Accelerometry will be analyzed by summing traces from each axis, after using Welch's method to calculate the power spectral density (PSD), with 3-7 Hz tremor frequency range selected for the area under the curve and transformed into logarithmic scale to account for the variability in tremor amplitude at baseline. The primary endpoint will be the percent change in PSD between the post-sonication recording after the 1st Round of the session and the baseline recording.
Measured: 5 minutes
Secondary outcomes (3)
Change in power spectral density (PSD) of tremor accelerometric trace between post-sonication (Round 2) and baseline
This outcome will be measured using triaxial accelerometry performed on the participants' index finger (treated side). Accelerometry will be analyzed by summing traces from each axis, after using Welch's method to calculate the power spectral density (PSD), with 3-7 Hz tremor frequency range selected for the area under the curve and transformed into logarithmic scale to account for the variability in tremor amplitude at baseline. The primary endpoint will be the percent change in PSD between the post-sonication recording after the 2nd Round of the session and the baseline recording.
Measured: 5 minutes
Change in Clinical Rating Scale for Tremor sub-score corresponding to the sum of scale items related to the treated side between the post-sonication rating and the baseline rating (participants with ET)
This applies only to participants with a diagnosis of Essential Tremor
Measured: 5 minutes
Change in the Movement Disorders Society-Unified Parkinson's Disease Rating Scale sub-score corresponding to the sum of resting tremor items of the scale between the post-sonication rating and the baseline rating (participants with PD).
This applies only to participants with a diagnosis of Parkinson's disease
Measured: 5 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2025
- Study start15 Sep 2025 (estimated)
- Primary completion15 Jul 2027 (estimated)
- Study completion15 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Essential TremorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- We use an in-house developed focused ultrasound system that uses a 128-element phased array transducer (diameter of 135 mm, F#=0.8) operating at 700 kHz and mounted on a specialized arm for stereotactic neuronavigation. Patients will be seated comfortably in a chair equipped with neuronavigation (BrainSight, Rogue) positioning the custom transcranial ultrasound (TUS) array. The TUS array will be applied to the scalp, with ultrasound gel applied, and held in place using the neuronavigation arm. The control session will have the same duration of the real stimulation session, i.e., it will be divided in two 40-minutes long rounds. During the first round, participants will receive sham stimulation which is unfocused, thereby providing the same sound but without sufficient intensity at any location. After the break, during the second round participants will receive TUS stimulation at the same energy parameters as in the real stimulation session but positioning the focus in the CSF space.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Calgary
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07103265
- Sponsor's protocol ID
- REB22-1437
- Status last verified
- Jun 2025
- First submitted
- 2 Jul 2025
- Last updated
- 5 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Developing a New Low-intensity Focused Ultrasound (LIFU) Neuromodulation Method to Suppress Tremor
- ClinicalTrials.gov ID
- NCT07103265
- Acronym / sponsor ID
- REB22-1437
- Conditions
- Essential Tremor
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University of CalgaryUniversity, hospital or other
- Study start
- 15 Sep 2025 (estimated)
- Primary completion
- 15 Jul 2027 (estimated)
- Study completion
- 15 Jul 2027 (estimated)
- First posted
- 5 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators aim to apply low intensity focused ultrasound neuromodulation to patients with essential tremor to evaluate the efficacy of this intervention in reducing the amplitude of hand tremor compared to sham stimulation.
Detailed description
Transcranial ultrasound stimulation is a non-invasive brain stimulation that uses low intensity focused ultrasound (LIFU) to modulate neural activity with high spatial precision (Zadeh et al., 2024). Several human and animal studies have demonstrated that LIFU can produce lasting neuromodulatory effects, including both excitatory and inhibitory responses in the primary motor cortex (Zadeh et al., 2024). Furthermore, evidence suggests that LIFU is capable of inducing plasticity in the human brain that resembles long term potentiation or long-term depression (Zeng et al., 2024). The ability of LIFU to induce bidirectional effects, either excitatory or inhibitory, depending on sonication parameters, offers a level of flexibility in tailoring neuromodulatory interventions to individual patient needs and specific neural circuit dysfunctions. Combined with real-time neuronavigation and acoustic modeling tools, LIFU provides a promising platform for precise, personalized, and non-invasive brain stimulation. The modulatory effect of LIFU depends on sonication parameters such as frequency, attenuation, and pulse repetition frequency (Zeng et al., 2024; Manuel et al., 2020), and evidence from both preclinical and clinical studies suggests these effects can persist beyond the stimulation period consistent with long-term potentiation or long-term depression-like plasticity mechanisms (Fomenko et al., 2020; Zadeh et al., 2024).
Unlike other neuromodulatory techniques such as transcranial magnetic stimulation and transcranial direct current stimulation, LIFU offers the unique capability to reach deep brain structures while maintaining a focal spatial resolution. This advantage of precise targeting of deep brain regions such as the thalamus without the need for surgical intervention make LIFU a highly useful modality for investigating disorders (Legon et al., 2018). Structures like the ventral intermediate nucleus (Vim) of the thalamus, commonly implicated in movement disorders such as essential tremor and Parkinson's disease, can be non-invasively stimulated using LIFU to modulate aberrant neural activity.
In a previous study, we piloted an ultrasound transducer integrated with standard optical tracking-based neuro-navigation to establish a safety and tolerability benchmark for LIFU to reduce tremor in patients with Essential Tremor or Parkinson's disease, while also optimizing stimulation parameters prior to broader clinical application. Our open label study, currently under review for publication, demonstrated high efficacy and safety of our system to transiently reduce, in the short term, tremor amplitude measured using accelerometric recordings. By integrating rigorous screening, controlled stimulation parameters, and standardized monitoring protocols, we propose here a randomized sham-controlled study to advance knowledge on efficacy and safety of this technology in a larger clinical sample of patients with these diagnoses. As LIFU continues to expand into therapeutic realms, such foundational research will be essential for supporting its evidence-based integration into neuroscience and medicine.
Objectives. AIM: To determine if we can low intensity focused ultrasound (LIFU, a neuromodulatory form of ultrasound) in the laboratory setting can transiently suppress tremor when targeting motor thalamus in patients with tremor.
HYPOTHESIS: Specific LIFU patterns applied to deep thalamic targets will transiently induce reduce tremor in patients with tremor.
IMPACT: If successful, we could use LIFU to help predict potential efficacy of permanent lesioning on tremor as well as support further investigation of LIFU as a novel non-invasive neuromodulation strategy for tremor.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- We use an in-house developed focused ultrasound system that uses a 128-element phased array transducer (diameter of 135 mm, F#=0.8) operating at 700 kHz and mounted on a specialized arm for stereotactic neuronavigation. Patients will be seated comfortably in a chair equipped with neuronavigation (BrainSight, Rogue) positioning the custom transcranial ultrasound (TUS) array. The TUS array will be applied to the scalp, with ultrasound gel applied, and held in place using the neuronavigation arm. The control session will have the same duration of the real stimulation session, i.e., it will be divided in two 40-minutes long rounds. During the first round, participants will receive sham stimulation which is unfocused, thereby providing the same sound but without sufficient intensity at any location. After the break, during the second round participants will receive TUS stimulation at the same energy parameters as in the real stimulation session but positioning the focus in the CSF space.
| Arm | Type | Receives |
|---|---|---|
| Real stimulation | Experimental | Device: Transcranial focused ultrasound stimulationWe use an in-house developed focused ultrasound system that uses a 128-element phased array transducer (diameter of 135 mm, F#=0.8) operating at 700 kHz and mounted on a specialized arm for stereotactic neuronavigation. It has been tested in normal subjects targeting cortical structures (REB#19-1614, #21-0959), and in thalamus for the pilot data collection for this project (REB#22-1437). Patients will be seated comfortably in a chair equipped with neuronavigation (BrainSight, Rogue) positioning the custom LIFU array. The LIFU array will be applied to the scalp, with hair parted and ultrasound gel applied, and held in place using the neuronavigation arm. |
| Sham stimulation | Sham comparator | Device: Sham stimulationSame setting as Real stimulation, but without delivering any ultrasound stimulation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Diagnosis of Essential Tremor OR Diagnosis of Parkinson's Disease
Key exclusion criteria (3 listed)
- Presence of any neurological diagnosis other than Essential Tremor and Parkinson's Disease
- Family history of Essential Tremor OR Parkinson's Disease
- Inability to undergo MRI or attend to the experimental study sessions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcranial focused ultrasound stimulationParameters Range of values Fundamental frequency 250 kHz Transducer diameter 15 cm Focal distance 13.5 cm (steerable +/- 5-10 mm from the center) Pulse repetition frequency 100 Hz Duty cycle 10% Duration 2 min for each of the 7 foci Peak spatial intensity (Isppa) 10.0 W/cm2 Peak temporal average intensity (Ispta) 1.2 W/cm2 Mechanical index (MI) 0.48 * Thermal index (TI) 0.8oC ** | Device | Real stimulation |
| Sham stimulationSame set-up as for real stimulation but with without delivering any ultrasound stimulation | Device | Sham stimulation |
Primary outcome
Change in power spectral density (PSD) of tremor accelerometric trace between post-sonication (Round 1) and baseline
Time frame: 5 minutes
This outcome will be measured using triaxial accelerometry performed on the participants' index finger (treated side). Accelerometry will be analyzed by summing traces from each axis, after using Welch's method to calculate the power spectral density (PSD), with 3-7 Hz tremor frequency range selected for the area under the curve and transformed into logarithmic scale to account for the variability in tremor amplitude at baseline. The primary endpoint will be the percent change in PSD between the post-sonication recording after the 1st Round of the session and the baseline recording.
3 secondary outcomes
Change in power spectral density (PSD) of tremor accelerometric trace between post-sonication (Round 2) and baseline
Time frame: 5 minutes
Change in Clinical Rating Scale for Tremor sub-score corresponding to the sum of scale items related to the treated side between the post-sonication rating and the baseline rating (participants with ET)
Time frame: 5 minutes
Change in the Movement Disorders Society-Unified Parkinson's Disease Rating Scale sub-score corresponding to the sum of resting tremor items of the scale between the post-sonication rating and the baseline rating (participants with PD).
Time frame: 5 minutes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2025.
Related trials for Essential Tremor
Active, not recruitingObservational study
Identifying Markers of Disease Subtypes and Disease Progression in the Syndrome of Essential Tremor
Essential Tremor
RecruitingPhase 2
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
Upper Limb Essential Tremor
Recruiting
Deep Brain Stimulation Surgery for Movement Disorders
Parkinson's Disease, Essential Tremor
RecruitingObservational study
Phenotype/Genotype Correlations in Movement Disorders
Movement Disorder
RecruitingObservational study
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
Essential Tremor, Movement Disorders, Essential Tremor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Transcranial focused ultrasound stimulation in people with Essential Tremor, run by University of Calgary.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in power spectral density (PSD) of tremor accelerometric trace between post-sonication (Round 1) and baseline (time frame: 5 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2025.